Tuesday, May 20, 2008 New Green Baron Stock Pick to be Released Tomorrow, May 21 at 10:30 am PST Fourth Pick of 2008 Expected to Trade Significantly Higher After Our Coverage Starts … Be Ready! Once again, we announce that The Green Baron Report will release its fourth fully profiled stock pick for 2008 on Wednesday, May 21 at 1:30 pm EST / 10:30 am PST. Our first two picks rallied strongly after release of our profiles, and hit highs of 95% and 58% respectively above our profile prices. We are still waiting for our third pick, Znomics, Inc. to join the party and we still anticipate a big move soon once investors start to understand the potential of ZNOM, and particularly the team of renowned experts the company has assembled to carry out its objectives. If you haven't already done so, we urge our members to listen to the Green Baron exclusive ZNOM webcast w/ CEO Richard Sessions. Then consider what ZNOM is doing right now and the huge companies they're already partnered with. (see below for more info) Our next new pick is traded on the OTC Bulletin Board at under $1 per share. This Company recently raised money at its current trading price, and we have concrete reasons to own this stock now. This is a Green Baron stock pick you do not want to miss.
Focus Pick Update Znomics, Inc. (BB: ZNOM) Mark Time and Date Now! Znomics to Hold Business Strategy Conference Call Thursday, May 22, 2008 Drug discovery stocks can be the most explosive of all situations. Znomics has a top tier management team, and we believe the Company’s research platform is going to unfold valuable new discoveries soon. We invite our members to listen and learn about Znomics through a conference call planned for after the market close this coming Thursday, May 22. (See press release reprinted below) ZNOM stock trades at prices of $2.50 to $2.90 per share. Don’t be surprised if you see Znomics initiate a move higher at any time. We encourage members to nibble at these prices in anticipation of new interest expected to come into the stock. PORTLAND, Ore., May 14, 2008 (PRIME NEWSWIRE) -- Znomics, Inc. (OTCBB:ZNOM), a pioneer in the development of the zebrafish as a vertebrate genetic platform to accelerate drug discovery, announced today that it will host a conference call to update investors on its business strategy on Thursday, May 22, 2008 at 1:30 p.m. PDT. The call is open to all interested parties and can be accessed by dialing 1-877-407-0778 (domestic) or 201-689-8565 (international). The webcast of the call can be accessed at www.znomics.com or http://www.investorcalendar.com/IC/CEPage.asp?ID=129765. Listeners are encouraged to visit the Web site at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A replay of the conference call will be archived until June 5, 2008 and can be accessed by calling 1-877-660-6853 and by entering account number 286 and conference ID number 285297. About Znomics Znomics, Inc. is focused on identifying and developing new pharmaceutical products for treatment of human disorders and diseases. The company's drug discovery platform is based on its catalogued library of mutations in the zebrafish, called the ZeneMark Library. The library, the first in a vertebrate, currently contains more than 11,000 strains of fish representing mutations in approximately half of the known genome. Zebrafish share 80% -- 90% of the same genes as humans. The company is leveraging this technology for its internal drug discovery efforts as well as establishing collaborative partnerships with pharmaceutical companies and universities. For more information, visit www.znomics.com Forward-Looking Statements With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. Any forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues or expenses, and products or service line growth, may be significantly and materially impacted by certain risks and uncertainties, including, but not limited to, failure to meet operating objectives or to execute the operating plan, competition, and other economic factors, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Additional risks and uncertainties are described in the Company's public filings with the Securities and Exchange Commission, available online at www.sec.gov. Znomics undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website at www.znomics.com For Further Information Contact: Znomics, Inc. Richard Sessions, Chief Executive Officer (503)827-5271 ext 102 Kerry Rea, Chief Financial Officer (503)827-5271 ext 101
Pondel/Wilkinson Inc. Investor Relations: Rob Whetstone Eileen Rauchberg (310)279-5980
|
